Adaptimmune Therapeutics PLC (NASDAQ:ADAP)’s share price rose 1.8% during mid-day trading on Monday . The company traded as high as $8.95 and last traded at $8.77. Approximately 654,097 shares changed hands during mid-day trading, an increase of 136% from the average daily volume of 277,270 shares. The stock had previously closed at $8.93.

ADAP has been the topic of a number of recent research reports. Cowen and Company reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, July 12th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Leerink Swann reissued an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a report on Friday. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics PLC has an average rating of “Hold” and a consensus target price of $12.08.

The firm’s market cap is $818.29 million. The firm’s 50 day moving average price is $5.70 and its 200-day moving average price is $5.18.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.24). The firm had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. Equities analysts forecast that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current year.

A number of large investors have recently added to or reduced their stakes in ADAP. Raymond James Financial Services Advisors Inc. acquired a new position in Adaptimmune Therapeutics PLC in the first quarter valued at about $120,000. KCG Holdings Inc. acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $133,000. Monashee Investment Management LLC acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $138,000. OxFORD Asset Management LLP acquired a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth approximately $156,000. Finally, Paloma Partners Management Co acquired a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth approximately $165,000. Hedge funds and other institutional investors own 68.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Stock Price Up -1.8%” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/11/adaptimmune-therapeutics-plc-adap-stock-price-up-1-8.html.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.